Table 1 Baseline demographic, tumor, and treatment characteristics of 374 NPC patients
Characteristic | Result |
|---|---|
Sex, N (%) | |
Female | 112 (29.9) |
Male | 262 (70.1) |
Age at diagnosis, years (median, range) | 46 (17–70) |
ALC baseline before treatment ×109 cells/L (median, range) | 1.81 (0.25–3.5) |
Body mass index, kg/m2 (median, range) | 22.60 (15.60–33.77) |
Smoking status, pack*year (median,range) | 0 (0–120) |
Tumor histologic type (WHO), N (%) | |
Non-keratinized undifferentiated (III) | 145 (38.8) |
Non-keratinized differentiated (II) | 220 (58.8) |
Keratinized (I) | 9 (2.41) |
T status, N (%) | |
T1 | 37 (9.9) |
T2 | 133 (35.6) |
T3 | 156 (41.7) |
T4 | 48 (12.8) |
N status, N (%) | |
N0 | 31 (82.9) |
N1 | 80 (21.4) |
N2 | 227 (60.7) |
N3 | 36 (9.6) |
Stagea, N (%) | |
II | 46 (12.3) |
III | 245 (65.5) |
IVa | 83 (22.2) |
Prescribed dose of GTVnx,Gy, (median, range) | 72.7 (68–82) |
Induction or concurrent chemotherapy, N (%) | |
None | 48 (12.8) |
Induction only | 62 (16.6) |
Concurrent only | 70 (18.7) |
Both | 194 (51.9) |
Adjuvant chemotherapy, N (%) | |
Yes | 131 (35.0) |
No | 243 (65.0) |
Radiation modality, N (%) | |
2D-CRT | 261 (69.8) |
IMRT | 113 (30.2) |